HIND 8-K SEC Filing Analysis

Latest settled — T+5d

HIND ▼ -3.42% at T+5d

SHORT call ✓ call won +3.42% · α vs SPY +3.13% · entry $2.34 → $2.26

Next anchor: T+20d in 16d

Currently $2.30 · +1.71% from $2.34 entry (call sign-flipped)

Entry anchored
May 28, 03:59 PM ET
via Databento tick

T+1d

-0.85%

call +0.85% · α +1.13%

$2.32

settled 12d ago

T+5d

-3.42%

call +3.42% · α +3.13%

$2.26

settled 8d ago

T+20d

—

call — · α —

—

in 16d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Vyome Holdings reported Q1 2026 EPS of -$0.15, beating the consensus estimate of -$0.19 by 21%, but revenue collapsed 84% YoY to $31.6K from $198.6K. The company highlighted FDA filings for Orphan Drug Designation on VT-1953, an in-licensing deal for JAK inhibitors with Impetis Biosciences (TATA Enterprise), and a $5.29M equity raise at a 59% premium — but the revenue decline and cash burn dominate the outlook for a $16M market-cap clinical-stage biotech.

Key Financial Metrics

Gross Margin

52.7%

Actionable Insight

The EPS beat is mechanical on a tiny base and irrelevant for a clinical-stage biotech. The key catalysts are FDA feedback on VT-1953 Orphan Drug Designation and whether the JAK inhibitor in-license progresses to clinical milestones. With only $8.8M cash and $1.1M quarterly burn, watch for warrant exercise or future dilutive offerings if pipeline milestones slip. The revenue collapse is not material for the thesis — pipeline milestones are the only driver for HIND.

Key Facts

Revenue fell 84% YoY to $31.6K (Q1 2026) from $198.6K (Q1 2025), though revenue remains immaterial for a clinical-stage biotech
EPS of -$0.15 beat consensus of -$0.19 by 21.1%
Net loss widened to -$985.5K from -$294.0K YoY, driven by operating expenses tripling to $1.15M
Cash & equivalents: $8.8M as of March 31, 2026, up from $5.0M at Dec 2025 after a $5.29M equity raise
Filed Orphan Drug Designation application with FDA for VT-1953 and in-licensed two JAK inhibitor assets from Impetis Biosciences (TATA) with payments at commercialization
Clean capital structure maintained — no debt, preferred, or toxic instruments

Financial Impact

Revenue declined ~84% YoY to $31.6K; net loss widened to -$985.5K; cash burn rate of ~$1.1M/quarter ($8.8M cash = ~8 quarters runway)

revenuenet_losscash_positionoperating_expenses

Risk Factors

VT-1953 Orphan Drug Designation may be denied or delayed
Cash runway extends only through ~8 quarters at current burn; clinical setbacks would force dilutive financing
Revenue disappearance to $31.6K reduces credibility of any near-term commercialization revenue
Post-market close May 28 — elevated after-hours volatility risk

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001213900-26-062458
Document: ea0292643-8k_vyome.htm	0001213900-26-062458
Document: 0001213900-26-062458-index-headers.html	0001213900-26-062458
Document: 0001213900-26-062458-index.html	0001213900-26-062458
Document: 0001213900-26-062458.txt	0001213900-26-062458
8-K Data (Synthetic)	0001213900-26-062458

2 reports for HIND

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for HIND — sortable, filterable
	Type				Now
May 29, 2026 15d ago	8-K BEARISH ★ 5/10	$2.34 $2.26	▲ +3.42%	▲ +3.13%	$2.30 (+1.71%)
Feb 25, 2026 15w ago	8-K BULLISH ★ 8/10	$3.36 $2.91	▼ −13.39%	▼ −12.27%	$2.30 (−31.55%)

US Market Status

Market Closed — Opens Mon (45h 28m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access